newsfilter
← Latest News
GlobeNewswire·

Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD

Phase 2 OraGrowtH210 and Phase 2 PK/PD OraGrowtH212 Trials Are Fully Enrolled Primary Outcome Data for Both OraGrowtH Trials Expected 4Q 2023 AUSTIN, Texas, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.